CS
BMY icon

Credit Suisse’s Bristol-Myers Squibb BMY Stock Holding History

Credit Suisse’s Portfolio BMY Stock Details BMY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-720,400
Closed -$44.9M – 3675
2021
Q4 		$44.9M Sell
720,400
-175,000
-20% -$10.3M 0.02% 696
2021
Q3 		$53M Buy
895,400
+602,100
+205% +$39.7M 0.03% 618
2021
Q2 		$19.4M Sell
293,300
-146,900
-33% -$9.58M 0.01% 1157
2021
Q1 		$27.8M Sell
440,200
-571,100
-56% -$35.5M 0.01% 993
2020
Q4 		$62.7M Buy
1,011,300
+75,400
+8% +$4.64M 0.03% 600
2020
Q3 		$56.4M Sell
935,900
-52,700
-5% -$3.17M 0.03% 562
2020
Q2 		$58.1M Buy
988,600
+570,100
+136% +$34.1M 0.04% 472
2020
Q1 		$23.3M Sell
418,500
-825,800
-66% -$50.5M 0.02% 759
2019
Q4 		$79.9M Buy
1,244,300
+516,300
+71% +$29.6M 0.06% 361
2019
Q3 		$36.9M Buy
728,000
+711,600
+4,339% +$33.4M 0.03% 598
2019
Q2 		$744K Sell
16,400
-133,600
-89% -$6.22M ﹤0.01% 3149
2019
Q1 		$7.16M Buy
150,000
+83,700
+126% +$4.17M 0.01% 1450
2018
Q4 		$3.45M Buy
+66,300
New +$3.56M ﹤0.01% 1856
2018
Q1 		– Sell
-250,000
Closed -$15.3M – 3964
2017
Q4 		$15.3M Sell
250,000
-193,500
-44% -$12.1M 0.01% 1020
2017
Q3 		$28.3M Buy
443,500
+182,500
+70% +$10.7M 0.03% 649
2017
Q2 		$14.5M Sell
261,000
-94,000
-26% -$5.12M 0.01% 986
2017
Q1 		$19.3M Buy
355,000
+195,000
+122% +$10.7M 0.02% 844
2016
Q4 		$9.35M Buy
160,000
+150,000
+1,500% +$8.2M 0.01% 1251
2016
Q3 		$539K Buy
+10,000
New +$642K ﹤0.01% 3375
2015
Q3 		– Sell
-100,000
Closed -$6.65M – 4271
2015
Q2 		$6.65M Buy
+100,000
New +$6.59M 0.01% 1520
2014
Q2 		– Sell
-40,000
Closed -$2.08M – 4656
2014
Q1 		$2.08M Buy
40,000
+30,700
+330% +$1.63M ﹤0.01% 2477
2013
Q4 		$494K Buy
+9,300
New +$474K ﹤0.01% 3784
2013
Q3 		– Sell
-242,100
Closed -$10.8M – 4206
2013
Q2 		$10.8M Buy
+242,100
New +$10.5M 0.01% 1087

Other funds holding BMY

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Credit Suisse's BMY Position: Q1 2024 in Review

Credit Suisse reduced its Bristol-Myers Squibb (BMY) stake by 27% in Q1 2024, selling an estimated $91.4M and leaving 4,884,813 shares worth $265M. The position accounts for 0.25% of the portfolio, ranked #68.

Credit Suisse first reported a position in BMY in Q2 2013 and has held it in 44 quarters since. The position peaked at $692M in Q4 2019. 2,331 funds tracked by Wall St. Rank hold BMY as of Q1 2024.

  • Credit Suisse held 4,884,813 shares of Bristol-Myers Squibb worth $265M as of Q1 2024.
  • Credit Suisse sold 1,793,918 Bristol-Myers Squibb shares in Q1 2024, an estimated $91.4M.
  • Bristol-Myers Squibb made up 0.25% of Credit Suisse's portfolio in Q1 2024, its #68 holding.
  • Credit Suisse first reported a position in Bristol-Myers Squibb in Q2 2013 and has held it in 44 quarters since.
  • Credit Suisse's Bristol-Myers Squibb position peaked at $692M in Q4 2019.
  • 2,331 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2024.

Based on Credit Suisse's 13F filing for Q1 2024, filed 10 May 2024.